

| Primary System Organ Class | Placebo N = 86 ¹ | Xanomeline High Dose N = 72 ¹ | Xanomeline Low Dose N = 96 ¹ | Overall N = 254 ¹ |
|--|---------------------------------------|--|---|--|
| Treatment Emergent AEs | 65 (76%) | 68 (94%) | 84 (88%) | 217 (85%) |
| GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | 21 (24%) | 36 (50%) | 51 (53%) | 108 (43%) |
| APPLICATION SITE PRURITUS | 6 (7.0%) | 21 (29%) | 23 (24%) | 50 (20%) |
| APPLICATION SITE ERYTHEMA | 3 (3.5%) | 14 (19%) | 13 (14%) | 30 (12%) |
| APPLICATION SITE DERMATITIS | 5 (5.8%) | 7 (9.7%) | 9 (9.4%) | 21 (8.3%) |
| APPLICATION SITE IRRITATION | 3 (3.5%) | 9 (13%) | 9 (9.4%) | 21 (8.3%) |
| APPLICATION SITE VESICLES | 1 (1.2%) | 5 (6.9%) | 5 (5.2%) | 11 (4.3%) |
| FATIGUE | 1 (1.2%) | 5 (6.9%) | 5 (5.2%) | 11 (4.3%) |
| OEDEMA PERIPHERAL | 2 (2.3%) | 2 (2.8%) | 1 (1.0%) | 5 (2.0%) |
| APPLICATION SITE SWELLING | 0 (0%) | 2 (2.8%) | 1 (1.0%) | 3 (1.2%) |
| APPLICATION SITE URTICARIA | 0 (0%) | 1 (1.4%) | 2 (2.1%) | 3 (1.2%) |
| CHILLS | 1 (1.2%) | 1 (1.4%) | 1 (1.0%) | 3 (1.2%) |
| MALAISE | 0 (0%) | 2 (2.8%) | 1 (1.0%) | 3 (1.2%) |
| PYREXIA | 2 (2.3%) | 0 (0%) | 1 (1.0%) | 3 (1.2%) |
| APPLICATION SITE PAIN | 0 (0%) | 2 (2.8%) | 0 (0%) | 2 (0.8%) |
| APPLICATION SITE PERSPIRATION | 0 (0%) | 2 (2.8%) | 0 (0%) | 2 (0.8%) |
| APPLICATION SITE REACTION | 1 (1.2%) | 1 (1.4%) | 0 (0%) | 2 (0.8%) |

¹ n (%)

| Primary System Organ Class Reported Term for the Adverse Event | Placebo N = 86 ¹ | Xanomeline High Dose N = 72 ¹ | Xanomeline Low Dose N = 96 ¹ | Overall N = 254 ¹ |
|---|---------------------------------------|--|---|--|
| ASTHENIA | 1 (1.2%) | 0 (0%) | 1 (1.0%) | 2 (0.8%) |
| CHEST DISCOMFORT | 0 (0%) | 1 (1.4%) | 1 (1.0%) | 2 (0.8%) |
| CHEST PAIN | 0 (0%) | 2 (2.8%) | 0 (0%) | 2 (0.8%) |
| OEDEMA | 0 (0%) | 0 (0%) | 2 (2.1%) | 2 (0.8%) |
| PAIN | 0 (0%) | 1 (1.4%) | 1 (1.0%) | 2 (0.8%) |
| APPLICATION SITE BLEEDING | 0 (0%) | 0 (0%) | 1 (1.0%) | 1 (0.4%) |
| APPLICATION SITE DESQUAMATION | 0 (0%) | 0 (0%) | 1 (1.0%) | 1 (0.4%) |
| APPLICATION SITE DISCHARGE | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |
| APPLICATION SITE DISCOLOURATION | 0 (0%) | 0 (0%) | 1 (1.0%) | 1 (0.4%) |
| APPLICATION SITE INDURATION | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| APPLICATION SITE WARMTH | 0 (0%) | 0 (0%) | 1 (1.0%) | 1 (0.4%) |
| FEELING ABNORMAL | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |
| FEELING COLD | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |
| INFLAMMATION | 0 (0%) | 0 (0%) | 1 (1.0%) | 1 (0.4%) |
| SECRETION DISCHARGE | 0 (0%) | 0 (0%) | 1 (1.0%) | 1 (0.4%) |
| SUDDEN DEATH | 0 (0%) | 0 (0%) | 1 (1.0%) | 1 (0.4%) |
| SWELLING | 0 (0%) | 0 (0%) | 1 (1.0%) | 1 (0.4%) |
| ULCER | 0 (0%) | 0 (0%) | 1 (1.0%) | 1 (0.4%) |
| SKIN AND SUBCUTANEOUS TISSUE DISORDERS | 20 (23%) | 39 (54%) | 39 (41%) | 98 (39%) |
| PRURITUS | 8 (9.3%) | 25 (35%) | 21 (22%) | 54 (21%) |

¹ n (%)

| Primary System Organ Class Reported Term for the Adverse Event | Placebo N = 86 ¹ | Xanomeline High Dose N = 72 ¹ | Xanomeline Low Dose N = 96 ¹ | Overall N = 254 ¹ |
|---|---------------------------------------|--|---|--|
| ERYTHEMA | 8 (9.3%) | 14 (19%) | 14 (15%) | 36 (14%) |
| RASH | 5 (5.8%) | 8 (11%) | 13 (14%) | 26 (10%) |
| HYPERHIDROSIS | 2 (2.3%) | 8 (11%) | 4 (4.2%) | 14 (5.5%) |
| SKIN IRRITATION | 3 (3.5%) | 5 (6.9%) | 6 (6.3%) | 14 (5.5%) |
| BLISTER | 0 (0%) | 1 (1.4%) | 5 (5.2%) | 6 (2.4%) |
| RASH PRURITIC | 0 (0%) | 2 (2.8%) | 1 (1.0%) | 3 (1.2%) |
| PRURITUS GENERALISED | 0 (0%) | 1 (1.4%) | 1 (1.0%) | 2 (0.8%) |
| URTICARIA | 0 (0%) | 1 (1.4%) | 1 (1.0%) | 2 (0.8%) |
| ACTINIC KERATOSIS | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |
| ALOPECIA | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| COLD SWEAT | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| DERMATITIS CONTACT | 0 (0%) | 0 (0%) | 1 (1.0%) | 1 (0.4%) |
| DRUG ERUPTION | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| RASH ERYTHEMATOUS | 0 (0%) | 0 (0%) | 1 (1.0%) | 1 (0.4%) |
| RASH MACULO-PAPULAR | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |
| SKIN EXFOLIATION | 0 (0%) | 0 (0%) | 1 (1.0%) | 1 (0.4%) |
| SKIN ODOUR ABNORMAL | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |
| SKIN ULCER | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| NERVOUS SYSTEM DISORDERS | 8 (9.3%) | 23 (32%) | 22 (23%) | 53 (21%) |

¹ n (%)

| Primary System Organ Class Reported Term for the Adverse Event | Placebo N = 86¹ | Xanomeline High Dose N = 72¹ | Xanomeline Low Dose N = 96¹ | Overall N = 254¹ |
|---|---------------------------------------|--|---|--|
| DIZZINESS | 2 (2.3%) | 10 (14%) | 9 (9.4%) | 21 (8.3%) |
| HEADACHE | 3 (3.5%) | 5 (6.9%) | 3 (3.1%) | 11 (4.3%) |
| SYNCOPE | 0 (0%) | 2 (2.8%) | 5 (5.2%) | 7 (2.8%) |
| SOMNOLENCE | 2 (2.3%) | 1 (1.4%) | 3 (3.1%) | 6 (2.4%) |
| TRANSIENT ISCHAEMIC ATTACK | 0 (0%) | 1 (1.4%) | 2 (2.1%) | 3 (1.2%) |
| BURNING SENSATION | 0 (0%) | 2 (2.8%) | 0 (0%) | 2 (0.8%) |
| LETHARGY | 0 (0%) | 1 (1.4%) | 1 (1.0%) | 2 (0.8%) |
| AMNESIA | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |
| BALANCE DISORDER | 0 (0%) | 0 (0%) | 1 (1.0%) | 1 (0.4%) |
| COGNITIVE DISORDER | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |
| COMPLEX PARTIAL SEIZURES | 0 (0%) | 0 (0%) | 1 (1.0%) | 1 (0.4%) |
| COORDINATION ABNORMAL | 0 (0%) | 0 (0%) | 1 (1.0%) | 1 (0.4%) |
| HEMIANOPIA HOMONYMOUS | 0 (0%) | 0 (0%) | 1 (1.0%) | 1 (0.4%) |
| HYPERSOMNIA | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |
| PARAESTHESIA | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |
| PARAESTHESIA ORAL | 0 (0%) | 0 (0%) | 1 (1.0%) | 1 (0.4%) |
| PARKINSON'S DISEASE | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| PAROSMIA | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |
| PARTIAL SEIZURES WITH SECONDARY GENERALISATION | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |
| PSYCHOMOTOR HYPERACTIVITY | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |

¹ n (%)

| Primary System Organ Class Reported Term for the Adverse Event | Placebo N = 86 ¹ | Xanomeline High Dose N = 72 ¹ | Xanomeline Low Dose N = 96 ¹ | Overall N = 254 ¹ |
|---|---------------------------------------|--|---|--|
| STUPOR | 0 (0%) | 0 (0%) | 1 (1.0%) | 1 (0.4%) |
| SYNCOPE VASOVAGAL | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |
| GASTROINTESTINAL DISORDERS | 17 (20%) | 19 (26%) | 15 (16%) | 51 (20%) |
| DIARRHOEA | 9 (10%) | 3 (4.2%) | 5 (5.2%) | 17 (6.7%) |
| VOMITING | 3 (3.5%) | 6 (8.3%) | 4 (4.2%) | 13 (5.1%) |
| NAUSEA | 3 (3.5%) | 6 (8.3%) | 3 (3.1%) | 12 (4.7%) |
| ABDOMINAL PAIN | 1 (1.2%) | 1 (1.4%) | 3 (3.1%) | 5 (2.0%) |
| SALIVARY HYPERSECRETION | 0 (0%) | 4 (5.6%) | 0 (0%) | 4 (1.6%) |
| DYSPEPSIA | 1 (1.2%) | 0 (0%) | 1 (1.0%) | 2 (0.8%) |
| ABDOMINAL DISCOMFORT | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |
| CONSTIPATION | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| DYSPHAGIA | 0 (0%) | 0 (0%) | 1 (1.0%) | 1 (0.4%) |
| FLATULENCE | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| GASTROINTESTINAL HAEMORRHAGE | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |
| GASTROESOPHAGEAL REFLUX DISEASE | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| GLOSSITIS | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| HIATUS HERNIA | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| RECTAL HAEMORRHAGE | 0 (0%) | 0 (0%) | 1 (1.0%) | 1 (0.4%) |
| STOMACH DISCOMFORT | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |

¹ n (%)

| Primary System Organ Class Reported Term for the Adverse Event | Placebo N = 86¹ | Xanomeline High Dose N = 72¹ | Xanomeline Low Dose N = 96¹ | Overall N = 254¹ |
|---|---------------------------------------|--|---|--|
| CARDIAC DISORDERS | 12 (14%) | 14 (19%) | 14 (15%) | 40 (16%) |
| SINUS BRADYCARDIA | 2 (2.3%) | 8 (11%) | 7 (7.3%) | 17 (6.7%) |
| MYOCARDIAL INFARCTION | 4 (4.7%) | 4 (5.6%) | 2 (2.1%) | 10 (3.9%) |
| ATRIAL FIBRILLATION | 1 (1.2%) | 2 (2.8%) | 2 (2.1%) | 5 (2.0%) |
| SUPRAVENTRICULAR EXTRASYSTOLES | 1 (1.2%) | 1 (1.4%) | 1 (1.0%) | 3 (1.2%) |
| VENTRICULAR EXTRASYSTOLES | 0 (0%) | 1 (1.4%) | 2 (2.1%) | 3 (1.2%) |
| ATRIAL FLUTTER | 0 (0%) | 1 (1.4%) | 1 (1.0%) | 2 (0.8%) |
| ATRIOVENTRICULAR BLOCK FIRST DEGREE | 1 (1.2%) | 0 (0%) | 1 (1.0%) | 2 (0.8%) |
| BUNDLE BRANCH BLOCK RIGHT | 1 (1.2%) | 0 (0%) | 1 (1.0%) | 2 (0.8%) |
| PALPITATIONS | 0 (0%) | 0 (0%) | 2 (2.1%) | 2 (0.8%) |
| ATRIAL HYPERTROPHY | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| ATRIOVENTRICULAR BLOCK SECOND DEGREE | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| BRADYCARDIA | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| BUNDLE BRANCH BLOCK LEFT | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| CARDIAC DISORDER | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |
| CARDIAC FAILURE CONGESTIVE | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| SINUS ARRHYTHMIA | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| SUPRAVENTRICULAR TACHYCARDIA | 0 (0%) | 0 (0%) | 1 (1.0%) | 1 (0.4%) |
| TACHYCARDIA | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |

¹ n (%)

| Primary System Organ Class | Placebo N = 86 ¹ | Xanomeline High Dose N = 72 ¹ | Xanomeline Low Dose N = 96 ¹ | Overall N = 254 ¹ |
|--|---------------------------------------|--|---|--|
| Reported Term for the Adverse Event | | | | |
| VENTRICULAR HYPERTROPHY | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| WOLFF-PARKINSON-WHITE SYNDROME | 0 (0%) | 0 (0%) | 1 (1.0%) | 1 (0.4%) |
| INFECTIONS AND INFESTATIONS | 16 (19%) | 13 (18%) | 9 (9.4%) | 38 (15%) |
| NASOPHARYNGITIS | 2 (2.3%) | 6 (8.3%) | 4 (4.2%) | 12 (4.7%) |
| UPPER RESPIRATORY TRACT INFECTION | 6 (7.0%) | 3 (4.2%) | 1 (1.0%) | 10 (3.9%) |
| INFLUENZA | 1 (1.2%) | 1 (1.4%) | 1 (1.0%) | 3 (1.2%) |
| URINARY TRACT INFECTION | 2 (2.3%) | 1 (1.4%) | 0 (0%) | 3 (1.2%) |
| CYSTITIS | 1 (1.2%) | 1 (1.4%) | 0 (0%) | 2 (0.8%) |
| EAR INFECTION | 2 (2.3%) | 0 (0%) | 0 (0%) | 2 (0.8%) |
| BRONCHITIS | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| CELLULITIS | 0 (0%) | 0 (0%) | 1 (1.0%) | 1 (0.4%) |
| CERVICITIS | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| GASTROENTERITIS VIRAL | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| HORDEOLUM | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |
| LOCALISED INFECTION | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| LOWER RESPIRATORY TRACT INFECTION | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |
| PNEUMONIA | 0 (0%) | 0 (0%) | 1 (1.0%) | 1 (0.4%) |
| RHINITIS | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |
| VAGINAL MYCOSIS | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| VIRAL INFECTION | 0 (0%) | 0 (0%) | 1 (1.0%) | 1 (0.4%) |

¹ n (%)

| Primary System Organ Class Reported Term for the Adverse Event | Placebo N = 86 ¹ | Xanomeline High Dose N = 72 ¹ | Xanomeline Low Dose N = 96 ¹ | Overall N = 254 ¹ |
|---|---------------------------------------|--|---|--|
| PSYCHIATRIC DISORDERS | 10 (12%) | 7 (9.7%) | 11 (11%) | 28 (11%) |
| CONFUSIONAL STATE | 2 (2.3%) | 1 (1.4%) | 3 (3.1%) | 6 (2.4%) |
| AGITATION | 2 (2.3%) | 0 (0%) | 3 (3.1%) | 5 (2.0%) |
| INSOMNIA | 2 (2.3%) | 2 (2.8%) | 0 (0%) | 4 (1.6%) |
| ANXIETY | 0 (0%) | 0 (0%) | 3 (3.1%) | 3 (1.2%) |
| DELUSION | 1 (1.2%) | 1 (1.4%) | 0 (0%) | 2 (0.8%) |
| IRRITABILITY | 1 (1.2%) | 0 (0%) | 1 (1.0%) | 2 (0.8%) |
| COMPLETED SUICIDE | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| DELIRIUM | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |
| DEPRESSED MOOD | 0 (0%) | 0 (0%) | 1 (1.0%) | 1 (0.4%) |
| DISORIENTATION | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| HALLUCINATION | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |
| HALLUCINATION, VISUAL | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |
| LIBIDO DECREASED | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |
| LISTLESS | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |
| NIGHTMARE | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |
| RESTLESSNESS | 0 (0%) | 0 (0%) | 1 (1.0%) | 1 (0.4%) |
| RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | 8 (9.3%) | 10 (14%) | 9 (9.4%) | 27 (11%) |
| COUGH | 1 (1.2%) | 5 (6.9%) | 5 (5.2%) | 11 (4.3%) |
| NASAL CONGESTION | 3 (3.5%) | 3 (4.2%) | 1 (1.0%) | 7 (2.8%) |

¹ n (%)

| Primary System Organ Class Reported Term for the Adverse Event | Placebo N = 86 ¹ | Xanomeline High Dose N = 72 ¹ | Xanomeline Low Dose N = 96 ¹ | Overall N = 254 ¹ |
|---|---------------------------------------|--|---|--|
| DYSPNOEA | 1 (1.2%) | 1 (1.4%) | 1 (1.0%) | 3 (1.2%) |
| EPISTAXIS | 0 (0%) | 2 (2.8%) | 1 (1.0%) | 3 (1.2%) |
| PHARYNGOLARYNGEAL PAIN | 0 (0%) | 1 (1.4%) | 1 (1.0%) | 2 (0.8%) |
| RHINORRHOEA | 0 (0%) | 1 (1.4%) | 1 (1.0%) | 2 (0.8%) |
| ALLERGIC GRANULOMATOUS ANGIITIS | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |
| DYSPHONIA | 0 (0%) | 0 (0%) | 1 (1.0%) | 1 (0.4%) |
| EMPHYSEMA | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| HAEMOPTYSIS | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| PHARYNGEAL ERYTHEMA | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |
| POSTNASAL DRIP | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| PRODUCTIVE COUGH | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |
| RALES | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| RESPIRATORY TRACT CONGESTION | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |
| INVESTIGATIONS | 10 (12%) | 5 (6.9%) | 7 (7.3%) | 22 (8.7%) |
| ELECTROCARDIOGRAM ST SEGMENT DEPRESSION | 4 (4.7%) | 0 (0%) | 1 (1.0%) | 5 (2.0%) |
| ELECTROCARDIOGRAM T WAVE INVERSION | 2 (2.3%) | 1 (1.4%) | 1 (1.0%) | 4 (1.6%) |
| BLOOD GLUCOSE INCREASED | 0 (0%) | 1 (1.4%) | 1 (1.0%) | 2 (0.8%) |
| ELECTROCARDIOGRAM T WAVE AMPLITUDE DECREASED | 1 (1.2%) | 0 (0%) | 1 (1.0%) | 2 (0.8%) |
| BIOPSY | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |
| BIOPSY PROSTATE | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |

¹ n (%)

| Primary System Organ Class Reported Term for the Adverse Event | Placebo N = 86 ¹ | Xanomeline High Dose N = 72 ¹ | Xanomeline Low Dose N = 96 ¹ | Overall N = 254 ¹ |
|---|---------------------------------------|--|---|--|
| BLOOD ALKALINE PHOSPHATASE INCREASED | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| BLOOD CHOLESTEROL INCREASED | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |
| BLOOD CREATINE PHOSPHOKINASE INCREASED | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| BLOOD URINE PRESENT | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| BODY TEMPERATURE INCREASED | 0 (0%) | 0 (0%) | 1 (1.0%) | 1 (0.4%) |
| CYSTOSCOPY | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| HEART RATE INCREASED | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| HEART RATE IRREGULAR | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| NASAL MUCOSA BIOPSY | 0 (0%) | 0 (0%) | 1 (1.0%) | 1 (0.4%) |
| WEIGHT DECREASED | 0 (0%) | 0 (0%) | 1 (1.0%) | 1 (0.4%) |
| MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS | 4 (4.7%) | 7 (9.7%) | 7 (7.3%) | 18 (7.1%) |
| BACK PAIN | 1 (1.2%) | 3 (4.2%) | 1 (1.0%) | 5 (2.0%) |
| ARTHRALGIA | 1 (1.2%) | 1 (1.4%) | 2 (2.1%) | 4 (1.6%) |
| SHOULDER PAIN | 1 (1.2%) | 0 (0%) | 2 (2.1%) | 3 (1.2%) |
| MUSCLE SPASMS | 0 (0%) | 1 (1.4%) | 1 (1.0%) | 2 (0.8%) |
| ARTHRITIS | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |
| FLANK PAIN | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |
| MUSCULAR WEAKNESS | 0 (0%) | 0 (0%) | 1 (1.0%) | 1 (0.4%) |
| MYALGIA | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |
| PAIN IN EXTREMITY | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |

¹ n (%)

| Primary System Organ Class Reported Term for the Adverse Event | Placebo N = 86 ¹ | Xanomeline High Dose N = 72 ¹ | Xanomeline Low Dose N = 96 ¹ | Overall N = 254 ¹ |
|---|---------------------------------------|--|---|--|
| INJURY, POISONING AND PROCEDURAL COMPLICATIONS | 4 (4.7%) | 5 (6.9%) | 5 (5.2%) | 14 (5.5%) |
| CONTUSION | 1 (1.2%) | 2 (2.8%) | 1 (1.0%) | 4 (1.6%) |
| EXCORIATION | 2 (2.3%) | 1 (1.4%) | 1 (1.0%) | 4 (1.6%) |
| FALL | 1 (1.2%) | 1 (1.4%) | 2 (2.1%) | 4 (1.6%) |
| HIP FRACTURE | 1 (1.2%) | 2 (2.8%) | 0 (0%) | 3 (1.2%) |
| SKIN LACERATION | 1 (1.2%) | 0 (0%) | 2 (2.1%) | 3 (1.2%) |
| FACIAL BONES FRACTURE | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |
| JOINT DISLOCATION | 0 (0%) | 0 (0%) | 1 (1.0%) | 1 (0.4%) |
| WOUND | 0 (0%) | 0 (0%) | 1 (1.0%) | 1 (0.4%) |
| RENAL AND URINARY DISORDERS | 4 (4.7%) | 3 (4.2%) | 3 (3.1%) | 10 (3.9%) |
| MICTURITION URGENCY | 1 (1.2%) | 1 (1.4%) | 1 (1.0%) | 3 (1.2%) |
| DYSURIA | 1 (1.2%) | 0 (0%) | 1 (1.0%) | 2 (0.8%) |
| NEPHROLITHIASIS | 1 (1.2%) | 1 (1.4%) | 0 (0%) | 2 (0.8%) |
| CALCULUS URETHRAL | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |
| INCONTINENCE | 0 (0%) | 0 (0%) | 1 (1.0%) | 1 (0.4%) |
| POLLAKIURIA | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| METABOLISM AND NUTRITION DISORDERS | 6 (7.0%) | 2 (2.8%) | 1 (1.0%) | 9 (3.5%) |
| DECREASED APPETITE | 1 (1.2%) | 1 (1.4%) | 0 (0%) | 2 (0.8%) |
| FOOD CRAVING | 1 (1.2%) | 0 (0%) | 1 (1.0%) | 2 (0.8%) |
| INCREASED APPETITE | 1 (1.2%) | 1 (1.4%) | 0 (0%) | 2 (0.8%) |
| DEHYDRATION | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |

¹ n (%)

| Primary System Organ Class Reported Term for the Adverse Event | Placebo N = 86 ¹ | Xanomeline High Dose N = 72 ¹ | Xanomeline Low Dose N = 96 ¹ | Overall N = 254 ¹ |
|---|---------------------------------------|--|---|--|
| DIABETES MELLITUS | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| HYPONATRAEMIA | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| VASCULAR DISORDERS | 3 (3.5%) | 1 (1.4%) | 3 (3.1%) | 7 (2.8%) |
| HYPOTENSION | 2 (2.3%) | 0 (0%) | 1 (1.0%) | 3 (1.2%) |
| HYPERTENSION | 1 (1.2%) | 0 (0%) | 1 (1.0%) | 2 (0.8%) |
| HOT FLUSH | 0 (0%) | 0 (0%) | 1 (1.0%) | 1 (0.4%) |
| ORTHOSTATIC HYPOTENSION | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| WOUND HAEMORRHAGE | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |
| EYE DISORDERS | 2 (2.3%) | 1 (1.4%) | 2 (2.1%) | 5 (2.0%) |
| VISION BLURRED | 0 (0%) | 1 (1.4%) | 1 (1.0%) | 2 (0.8%) |
| CONJUNCTIVAL HAEMORRHAGE | 0 (0%) | 0 (0%) | 1 (1.0%) | 1 (0.4%) |
| CONJUNCTIVITIS | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| EYE ALLERGY | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| EYE PRURITUS | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| EYE SWELLING | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| SURGICAL AND MEDICAL PROCEDURES | 2 (2.3%) | 2 (2.8%) | 1 (1.0%) | 5 (2.0%) |
| CATARACT OPERATION | 1 (1.2%) | 0 (0%) | 1 (1.0%) | 2 (0.8%) |
| ACROCHORDON EXCISION | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |
| EYE LASER SURGERY | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| SKIN LESION EXCISION | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |
| EAR AND LABYRINTH DISORDERS | 1 (1.2%) | 1 (1.4%) | 2 (2.1%) | 4 (1.6%) |
| VERTIGO | 0 (0%) | 1 (1.4%) | 1 (1.0%) | 2 (0.8%) |

¹ n (%)

| Primary System Organ Class Reported Term for the Adverse Event | Placebo N = 86 ¹ | Xanomeline High Dose N = 72 ¹ | Xanomeline Low Dose N = 96 ¹ | Overall N = 254 ¹ |
|---|---------------------------------------|--|---|--|
| CERUMEN IMPACTION | 0 (0%) | 0 (0%) | 1 (1.0%) | 1 (0.4%) |
| EAR PAIN | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| CONGENITAL, FAMILIAL AND GENETIC DISORDERS | 0 (0%) | 2 (2.8%) | 1 (1.0%) | 3 (1.2%) |
| VENTRICULAR SEPTAL DEFECT | 0 (0%) | 2 (2.8%) | 1 (1.0%) | 3 (1.2%) |
| NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS) | 0 (0%) | 1 (1.4%) | 2 (2.1%) | 3 (1.2%) |
| COLON CANCER | 0 (0%) | 0 (0%) | 1 (1.0%) | 1 (0.4%) |
| MALIGNANT FIBROUS HISTIOCYTOMA | 0 (0%) | 0 (0%) | 1 (1.0%) | 1 (0.4%) |
| PROSTATE CANCER | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |
| REPRODUCTIVE SYSTEM AND BREAST DISORDERS | 2 (2.3%) | 1 (1.4%) | 0 (0%) | 3 (1.2%) |
| BENIGN PROSTATIC HYPERPLASIA | 1 (1.2%) | 1 (1.4%) | 0 (0%) | 2 (0.8%) |
| PELVIC PAIN | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| HEPATOBILIARY DISORDERS | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| HYPERBILIRUBINAEMIA | 1 (1.2%) | 0 (0%) | 0 (0%) | 1 (0.4%) |
| IMMUNE SYSTEM DISORDERS | 0 (0%) | 0 (0%) | 1 (1.0%) | 1 (0.4%) |
| HYPERSENSITIVITY | 0 (0%) | 0 (0%) | 1 (1.0%) | 1 (0.4%) |
| SOCIAL CIRCUMSTANCES | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |
| ALCOHOL USE | 0 (0%) | 1 (1.4%) | 0 (0%) | 1 (0.4%) |

¹ n (%)